cyclosporine has been researched along with Parkinson Disease in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (33.33) | 18.2507 |
| 2000's | 7 (29.17) | 29.6817 |
| 2010's | 6 (25.00) | 24.3611 |
| 2020's | 3 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Agrawal, BK; Chakrabarti, S; Chakrabarti, SS; Chandan, G; Ganguly, U; Pal, S; Saini, RV; Singh, S; Thakur, R | 1 |
| Chen, G; He, Q; Li, PA; Zhang, M | 1 |
| Andreas, LB; Baker, JD; Becker, S; Blair, LJ; Favretto, F; Flores, D; Strohäker, T; Zweckstetter, M | 1 |
| Cappai, R; Chakrabarti, S; Ganguly, A; Ganguly, G; Ganguly, U; Sahoo, A; Sen, O | 1 |
| Chang, CY; Chen, S; Hsieh, W; Lin, SZ; Wang, Y; Wang, YC; Yang, CS; Yu, SJ | 1 |
| Cai, H; Ding, J; Lin, X; Liu, G; Luo, J; Parisiadou, L; Sun, L; Xie, C; Yu, J | 1 |
| Agrawal, S; Dixit, A; Patel, DK; Singh, A; Singh, D; Singh, MP; Tripathi, P | 1 |
| Bergstrand, S; Björklund, A; Churchill, MJ; Colino-Sanguino, Y; Decressac, M; Herz, NJ; Ippolito, R; Meshul, CK; Sconce, MD; Tamburrino, A; Wan, OW; Wolf, DA | 1 |
| Barron, A; Caldwell, GA; Caldwell, KA; Galiano, F; Lee, YJ; Patel, D; Wang, S; Witt, SN; Xu, C; Zhang, S | 1 |
| Hirabayashi, H; Ishizaka, S; Matsuda, R; Nakase, H; Nishimura, F; Nonaka, J; Ouji, Y; Sakaki, T; Toriumi, H; Yamada, S; Yoshikawa, M | 1 |
| Bartus, RT; Borlongan, CV; Emerich, DF; Hoffer, BJ | 1 |
| Barker, RA; Harrower, TP; Hooks, Y; Tyers, P | 1 |
| Ansari, AA; Breeze, RE; Freed, CR; Hutchinson, M; Kriek, EH; Mayne, A; Mazziotta, JC; O'Brien, CF; Schneck, SA; Zhang, YB | 1 |
| Earl, CD; Kupsch, A; Oertel, WH; Sautter, J | 1 |
| Burns, LH; Deacon, TW; Dinsmore, J; Galpern, WR; Isacson, O | 1 |
| Borlongan, CV; Cahill, DW; Cameron, DF; Freeman, TB; Sanberg, PR; Saporta, S; Stahl, CE | 1 |
| Borlongan, CV; Cahill, DW; Freeman, TB; Hauser, RA; Sanberg, PR | 1 |
| Cooper, JM; Schapira, AH; Seaton, TA | 1 |
| Berman, SB; Hastings, TG | 1 |
| Honey, CR; Levy, JG; Margaron, P; Obochi, MO; Shen, H; Yip, S | 1 |
| Ambrosio, S; Ferrer, I; Gil, J; Gómez, C; Piqué, M; Reiriz, J | 1 |
| Brown, AM; Burke, WJ; Conway, AD; Jain, JC; Kristal, BS; Li, SW; Ulluci, PA | 1 |
| Dawson, TM; Engelender, S; Igarashi, S; L Dawson, V; Rao, RK; Ross, CA; Sawa, A; Tanaka, Y; Tanzi, RE; Wanner, T | 1 |
| Bunney, BS; Gjedde, A; Leranth, C; Marek, KL; Naftolin, F; Price, LH; Robbins, RJ; Roth, RH; Spencer, DD; Vollmer, T | 1 |
3 review(s) available for cyclosporine and Parkinson Disease
| Article | Year |
|---|---|
NanoCsA improves the survival of human iPSC transplant in hemiparkinsonian rats.
Topics: Animals; Cell Differentiation; Corpus Striatum; Cyclosporine; Disease Models, Animal; Graft Survival; Humans; Induced Pluripotent Stem Cells; Male; Nanoparticles; Neurons; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Stem Cell Transplantation; Transplantation, Heterologous | 2019 |
[Neuronal transplantation in animal models of Parkinson disease: in vivo voltammetry, tissue cryopreservation and immunology].
Topics: Animals; Brain Tissue Transplantation; Cryopreservation; Cyclosporine; Disease Models, Animal; Dopamine; Fetal Tissue Transplantation; Graft Rejection; Humans; Immunosuppressive Agents; Mesencephalon; Parkinson Disease; Parkinson Disease, Secondary; Rats | 1995 |
CNS immunological modulation of neural graft rejection and survival.
Topics: Adrenal Medulla; Adult; Animals; Antibodies, Monoclonal; Brain; Brain Tissue Transplantation; Cell Transplantation; Cyclosporine; Dopamine; Drug Compounding; Fetal Tissue Transplantation; Genetic Therapy; Genetic Vectors; Graft Rejection; Graft Survival; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Male; Mesencephalon; Mice; Parkinson Disease; Primates; Rats; Sertoli Cells; Transplantation, Heterologous; Transplantation, Heterotopic; Tyrosine 3-Monooxygenase | 1996 |
3 trial(s) available for cyclosporine and Parkinson Disease
| Article | Year |
|---|---|
Lack of a detectable systemic humoral/cellular allogeneic response in human and nonhuman primate recipients of embryonic mesencephalic allografts for the therapy of Parkinson's disease.
Topics: Animals; Antibody Formation; Antibody-Dependent Cell Cytotoxicity; Brain Tissue Transplantation; Cell Line; Cyclosporine; Cytotoxicity, Immunologic; Fetal Tissue Transplantation; Follow-Up Studies; Humans; Immunity, Cellular; Levodopa; Lymph Nodes; Mesencephalon; Parkinson Disease; Prednisone; Primates; Spleen; T-Lymphocytes, Cytotoxic; Time Factors; Transplantation, Homologous | 1995 |
Cyclosporine-A increases locomotor activity in rats with 6-hydroxydopamine-induced hemiparkinsonism: relevance to neural transplantation.
Topics: Animals; Brain; Cyclosporine; Dextroamphetamine; Dopamine Agonists; Immunosuppressive Agents; Locomotion; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Tissue Transplantation | 1996 |
Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease.
Topics: Activities of Daily Living; Adult; Antiparkinson Agents; Caudate Nucleus; Cryopreservation; Cyclosporine; Dopamine; Female; Fetal Tissue Transplantation; Homovanillic Acid; Humans; Magnetic Resonance Imaging; Male; Mesencephalon; Middle Aged; Motor Activity; Parkinson Disease; Putamen; Stereotaxic Techniques; Tomography, Emission-Computed | 1992 |
18 other study(ies) available for cyclosporine and Parkinson Disease
| Article | Year |
|---|---|
Protective effects of cyclosporine A on neurodegeneration and motor impairment in rotenone-induced experimental models of Parkinson's disease.
Topics: Animals; Cyclosporine; Humans; Models, Theoretical; Motor Disorders; Neuroblastoma; Neuroprotective Agents; Parkinson Disease; Rats; Rats, Wistar; Rotenone | 2022 |
Suppression of NLRP3 Inflammasome, Pyroptosis, and Cell Death by NIM811 in Rotenone-Exposed Cells as an in vitro Model of Parkinson's Disease.
Topics: Animals; Caspase 1; Cell Death; Cell Survival; Cyclosporine; Humans; Inflammasomes; Interleukin-1beta; Mice; NLR Family, Pyrin Domain-Containing 3 Protein; Parkinson Disease; Pyroptosis; Reactive Oxygen Species; Rotenone; Signal Transduction | 2020 |
Catalysis of proline isomerization and molecular chaperone activity in a tug-of-war.
Topics: alpha-Synuclein; Amyloid; Catalysis; Cyclophilin A; Cyclosporine; Humans; Isomerism; Kinetics; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Chaperones; Parkinson Disease; Proline; Protein Aggregates; Protein Binding; Protein Domains | 2020 |
Dopamine Cytotoxicity on SH-SY5Y Cells: Involvement of α-Synuclein and Relevance in the Neurodegeneration of Sporadic Parkinson's Disease.
Topics: alpha-Synuclein; Cell Line, Tumor; Cell Survival; Cyclosporine; Dopamine; Humans; Membrane Potential, Mitochondrial; Parkinson Disease | 2019 |
A calcineurin- and NFAT-dependent pathway is involved in α-synuclein-induced degeneration of midbrain dopaminergic neurons.
Topics: alpha-Synuclein; Animals; Apoptosis; Calcineurin; Calcineurin Inhibitors; Cyclosporine; Dopaminergic Neurons; Gene Expression Regulation; HEK293 Cells; Humans; Mesencephalon; Mice; Mice, Transgenic; Mutation; NFATC Transcription Factors; Parkinson Disease; Primary Cell Culture; Signal Transduction | 2014 |
Cyclosporine A and MnTMPyP Alleviate α-Synuclein Expression and Aggregation in Cypermethrin-Induced Parkinsonism.
Topics: alpha-Synuclein; Animals; Corpus Striatum; Cyclosporine; Dopaminergic Neurons; Metalloporphyrins; Mitochondria; Oxidative Stress; Parkinson Disease; Parkinsonian Disorders; Pyrethrins; Rats, Wistar; Substantia Nigra | 2015 |
Cyclosporin promotes neurorestoration and cell replacement therapy in pre-clinical models of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Cell Transplantation; Cells, Cultured; Cognition Disorders; Cyclosporine; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Enzyme Inhibitors; Female; Humans; Mesencephalon; Mice; Mice, Inbred C57BL; Mice, Transgenic; Motor Activity; Nerve Tissue Proteins; Neurons; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Time Factors; Tyrosine 3-Monooxygenase | 2015 |
Chemical Compensation of Mitochondrial Phospholipid Depletion in Yeast and Animal Models of Parkinson's Disease.
Topics: alpha-Synuclein; Animals; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Carboxy-Lyases; Cyclosporine; Disease Models, Animal; Dopaminergic Neurons; Endoplasmic Reticulum Stress; Meclofenoxate; Membrane Proteins; Mitochondria; Mitochondrial Proteins; Parkinson Disease; Phosphatidylcholines; Phosphatidylethanolamines; Protective Agents; Saccharomyces cerevisiae; Solubility; Sulfaphenazole; Transferases (Other Substituted Phosphate Groups) | 2016 |
Treatment of Parkinson's disease model mice with allogeneic embryonic stem cells: necessity of immunosuppressive treatment for sustained improvement.
Topics: Animals; Apomorphine; Corpus Striatum; Cyclosporine; Disease Models, Animal; Embryonic Stem Cells; Immunosuppressive Agents; Lymphocyte Activation; Male; Mice; Mice, Inbred Strains; Motor Activity; Oxidopamine; Parkinson Disease; Stem Cell Transplantation; Time Factors; Transplantation, Homologous; Tyrosine 3-Monooxygenase | 2009 |
Bradykinin receptor agonist facilitates low-dose cyclosporine-A protection against 6-hydroxydopamine neurotoxicity.
Topics: Adrenergic Agents; Animals; Behavior, Animal; Blood-Brain Barrier; Bradykinin; Calcineurin; Corpus Striatum; Cyclosporine; Disease Models, Animal; Drug Synergism; Immunohistochemistry; Male; Motor Activity; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptor, Bradykinin B2; Receptors, Bradykinin; Substantia Nigra; Tyrosine 3-Monooxygenase | 2002 |
Long-term survival and integration of porcine expanded neural precursor cell grafts in a rat model of Parkinson's disease.
Topics: Animals; Brain; CD8 Antigens; Cell Differentiation; Cyclosporine; Ectodysplasins; Embryo, Mammalian; Female; Graft Rejection; Immunosuppressive Agents; Membrane Proteins; Myelin Sheath; Nerve Fibers; Neurons; Oxidopamine; Parkinson Disease; Pregnancy; Rats; Rats, Sprague-Dawley; Stem Cell Transplantation; Stereotyped Behavior; Swine; Sympathectomy, Chemical; Sympatholytics; Synapses; Transplantation, Heterologous; Tumor Necrosis Factors; Tyrosine 3-Monooxygenase | 2006 |
Xenotransplantation of porcine fetal ventral mesencephalon in a rat model of Parkinson's disease: functional recovery and graft morphology.
Topics: Animals; Brain Tissue Transplantation; Cyclosporine; Disease Models, Animal; Female; Mesencephalon; Parkinson Disease; Rats; Rats, Sprague-Dawley; Swine; Time Factors; Transplantation, Heterologous | 1996 |
Cyclosporin inhibition of apoptosis induced by mitochondrial complex I toxins.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Apoptosis; Coloring Agents; Cyclosporine; Dopamine Agents; Enzyme Inhibitors; Fluorescein-5-isothiocyanate; Fluorescent Dyes; In Situ Nick-End Labeling; Intracellular Membranes; Mitochondria; NAD(P)H Dehydrogenase (Quinone); Oxidative Stress; Parkinson Disease; PC12 Cells; Propidium; Rats; Rotenone; Uncoupling Agents | 1998 |
Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease.
Topics: Animals; Brain; Cell Membrane Permeability; Cyclosporine; Dopamine; In Vitro Techniques; Male; Mitochondria; Mitochondria, Liver; Mitochondrial Swelling; Monoamine Oxidase; Monophenol Monooxygenase; Oxidation-Reduction; Oxygen Consumption; Parkinson Disease; Rats; Rats, Sprague-Dawley | 1999 |
Reduced xenograft rejection in rat striatum after pretransplant photodynamic therapy of murine neural xenografts.
Topics: Analysis of Variance; Animals; Brain Tissue Transplantation; Corpus Striatum; Cyclosporine; Dopamine; Graft Rejection; Graft Survival; Immunosuppressive Agents; Male; Mice; Parkinson Disease; Photochemotherapy; Photosensitizing Agents; Porphyrins; Rats; Rats, Wistar; Transplantation, Heterologous; Verteporfin | 2000 |
Low concentrations of 1-methyl-4-phenylpyridinium ion induce caspase-mediated apoptosis in human SH-SY5Y neuroblastoma cells.
Topics: 1-Methyl-4-phenylpyridinium; Amino Acid Chloromethyl Ketones; Apoptosis; Caspase 8; Caspase 9; Caspase Inhibitors; Caspases; Cyclosporine; Cysteine Proteinase Inhibitors; Cytochrome c Group; DNA Fragmentation; Dose-Response Relationship, Drug; Fas Ligand Protein; fas Receptor; Humans; Membrane Glycoproteins; Membrane Potentials; Mitochondria; Neoplasm Proteins; Nerve Tissue Proteins; Neuroblastoma; Oligopeptides; Osmolar Concentration; Parkinson Disease; Tumor Cells, Cultured | 2001 |
Selective dopaminergic vulnerability: 3,4-dihydroxyphenylacetaldehyde targets mitochondria.
Topics: 3,4-Dihydroxyphenylacetic Acid; 4-Aminobenzoic Acid; Aminobenzoates; Animals; Aristolochic Acids; Cell Death; Cell Differentiation; Cyclosporine; Dopamine; Dopamine Antagonists; Enzyme Inhibitors; Ion Channels; Male; Membrane Proteins; Mitochondria; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Nerve Growth Factor; para-Aminobenzoates; Parkinson Disease; PC12 Cells; Phenanthrenes; Rats; Rats, Inbred F344; Respiration; Rotenone; Trifluoperazine; Uncoupling Agents | 2001 |
Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis.
Topics: Acetylcysteine; alpha-Synuclein; Animals; Apoptosis; Blotting, Western; Caspase 3; Caspase 9; Caspases; Cyclosporine; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Gene Expression Regulation; Immunoenzyme Techniques; Membrane Potentials; Mitochondria; Multienzyme Complexes; Mutation; Nerve Tissue Proteins; Parkinson Disease; PC12 Cells; Proteasome Endopeptidase Complex; Rats; Synucleins; Tetracycline; Transfection | 2001 |